L.A. McKeown

More than 80% of patients had persistent hypertension after discharge, with 14% progressing to the severe category.

The emerging DCB era puts operator skills in the spotlight as key to interpreting outcomes data, says Mamas Mamas.

The device represents a huge advance, but not quite a panacea, for clinicians dealing with a common issue, says Ajay Kirtane.

The approval is supported by an interim analysis of AGENT IDE, which showed less TLF at 12 months versus an uncoated balloon.

The AI-guided stethoscope doubled the ability to diagnose low ejection fraction in Nigeria, where maternal mortality is high.

The trial should signal a paradigm shift in how women with hypertensive disorders of pregnancy are managed long-term.

With complication rates of 1% or less, Neuroguard and CGuard are renewing optimism about CAS, experts said at VIVA 2023.

The uptick in stent thrombosis with this amphilimus-eluting stent means it’s unlikely US regulators will approve it, says Ajay Kirtane.

Teams can help patients navigate PAD and chronic stress through openness and learning from each other, says Kim Smolderen.

The data are a “call to arms” to diagnose and treat earlier, with the possibility of TAVI on the horizon, says Gilbert Tang.